ASX-listed clinical-stage biotech company Chimeric Therapeutics Limited (ASX:CHM) is engaged in developing ground-breaking CAR-T cell therapies for solid tumours. Chimeric Therapeutics’ CLTX-CAR-T technology incorporates a novel CAR-T recognition domain, chlorotoxin (CLTX), a peptide derived a scorpion’s venom. The Company is currently conducting Phase 1 clinical trials in glioblastoma (GBM) at the City of Hope Cancer Centre in Los Angeles, California.

Load More
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK